Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Early mortality rates at 30 and 60 days were lower with CPX‐351 vs 7 + 3, although the difference did not reach statistical significance. 33 Although CPX‐351 has primarily been studied as intensive chemotherapy, a phase 2 study evaluated lower‐intensity doses of CPX‐351 in adults with newly diagnosed AML who were considered less fit and had a composite treatment‐related mortality score of >13.1 (corresponding to a >13.1% proba

also in 111,027 other papers